A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types


Alberto Puccini, Joanne Xiu, Arielle Lutterman Heeke, Andreas Seeber, Richard M. Goldberg, Wafik S. El-Deiry, Stephan V Liu, Sarah Sammons, Emil Lou, Philip Agop Philip, John Marshall, Anthony Frank Shields, Heinz-Josef Lenz, Thomas J. Herzog, W. Michael Korn, Mohamed E Salem

Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective therapies for some patients with both germline and somatic BRCA1/2 mutations (MTs) or with homologous recombination repair deficiency (HRD). We aimed to characterize molecular differences between BRCA1 and BRCA2 MTs and their prognostic and/or predictive impact on PARPi outcomes in various cancer subtypes using real world data (RWD).

Download Publication